Editorial
The full cost and burden of disorders of the brain in Europe exposed for the first time

https://doi.org/10.1016/j.euroneuro.2011.09.005Get rights and content

References (6)

There are more references available in the full text version of this article.

Cited by (18)

  • Prevalence of mental disorders and associated disability: Results from the cross-sectional CZEch mental health Study (CZEMS)

    2019, European Psychiatry
    Citation Excerpt :

    Mental disorders are amongst the top causes of disability in terms of Disability Adjusted Life Years (DALYs) globally [1,2] and depression is now the leading cause of disability [3]. Approximately 25% of people experience a mental disorder every year [4,5], but the majority of people affected do not receive help due to an array of factors, including stigmatization of mental illness and a lack of access to adequate services [6,7]. World Mental Health Surveys conducted under the umbrella of the World Health Organization (WHO) demonstrated an association between severity of mental disorders and help-seeking behaviour [8], and disability has been considered equally important as mortality for public health [9].

  • The relationship between impulsivity and panic disorder-agoraphobia: The role of affective temperament

    2018, Psychiatry Research
    Citation Excerpt :

    Even though harm avoidance and behavioral inhibition are observed in anxiety disorders (Taylor et al., 2008), it has been suggested that patients with anxiety are more impulsive compared to healthy controls (Del Carlo et al., 2013). Epidemiological data indicate that panic disorder (PD) is one of the anxiety disorders that disrupts functionality the most (Nutt, 2011). The relationship between panic disorder and impulsivity has not been sufficiently investigated (Del Carlo et al., 2013).

  • Impulsivity in drug-naïve panic disorder

    2017, European Journal of Psychiatry
    Citation Excerpt :

    Panic disorder (PD) is common and disabling condition being associated with high burdens and characterized by a variable pattern of symptomatology.1

  • In vitro screening of nanomedicines through the blood brain barrier: A critical review

    2016, Biomaterials
    Citation Excerpt :

    With an average of 13 years and an investment above $1 billion to develop a treatment, disorders of the central nervous system (CNS) represent the disease area whose unmet medical needs call for the most lengthy and resource-consuming procedures [1–4].

  • The clinical effectiveness of concise cognitive behavioral therapy with or without pharmacotherapy for depressive and anxiety disorders; a pragmatic randomized controlled equivalence trial in clinical practice

    2016, Contemporary Clinical Trials
    Citation Excerpt :

    Fortunately, several effective psycho- and pharmacotherapeutic treatments are widely applied for these disorders [7]. However, they place a high demand on healthcare services [15,27,32]. Offering these treatments in a more concise form without compromising effectiveness might mitigate this problem [5].

View all citing articles on Scopus
View full text